FDA approves Pfizer’s vaccine for the prevention of RSV in children
Betsy Goodfellow | August 22, 2023 | News story | Research and Development | FDA, Paediatrics, Pfizer, RSV
On Monday, Pfizer announced that the US Food and Drug Administration (FDA) has approved Abrysvo for the prevention of respiratory syncytial virus (RSV) in infants. The vaccine will work through the immunisation of pregnant women at 32 to 36 weeks of pregnancy.
The chief scientific officer of Vaccine Research and Development at Pfizer, Annaliesa Anderson, commented: “Abrysvo’s approval as the first and only maternal immunisation to help protect newborns immediately at birth through six months from RSV marks a significant milestone for the scientific community and for public health. We are incredibly grateful to the clinical trial participants and study investigator teams around the world, as well as our Pfizer colleagues, for their commitment to making this vaccine available. Today, a long-sought-after goal to deliver a maternal vaccine that will help protect infants six months of age or younger – when they are at greatest risk of possible serious consequences from RSV – has been achieved.”
The FDA’s approval followed the phase 3 clinical trial MATISSE, a randomised, double-blinded, placebo-controlled study designed to evaluate the vaccine’s efficacy and safety when received by pregnant patients. Children affected by RSV can be faced with lung and breathing issues, which can proceed to cause death or severe illnesses.
Eric A F Simões, clinical professor at University of Colorado School of Medicine, stated: “Newborns and young infants – whose immune systems are still developing and are not yet strong enough to defend against infections – may now be protected from RSV from the moment of birth through maternal immunisation. The approval of Pfizer’s Abrysvo is a major triumph as it helps ensure no delay in potential RSV protection during an infant’s most vulnerable first six months of life and offers healthcare providers a new opportunity to help prevent severe RSV.”
Rebecca Lee
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
